Stockreport

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain

Contineum Therapeutics, Inc. - Common stock  (CTNM) 
PDF - Phase 1b study for the potential treatment of osteoarthritis and low back pain expected to commence in the first quarter of 2025- Initial data readout planned for earl [Read more]